Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for SUNPHARMA
Revenue projections for SUNPHARMA

With Sun Pharmaceutical Industries Limited's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 2.824000
forwardPE 28.464653
debtToEquity 5.517000
earningsGrowth 0.256000
revenueGrowth 0.128000
grossMargins 0.802540
operatingMargins 0.188340
trailingEps 47.860000
forwardEps 64.792640

SUNPHARMA's current ratio being 2.824 suggests that it has more than enough liquidity to cover short-term debt obligations. The company's cash reserves and current assets are sufficient to meet immediate liabilities, signaling solid financial health and minimal risk.
SUNPHARMA's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
Positive earnings and revenue growth for SUNPHARMA point to expected business expansion. The company is projected to continue growing its operations, as increasing profits and sales highlight a strong trajectory for further growth in the future.
SUNPHARMA's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in SUNPHARMA's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for SUNPHARMA
Price projections for SUNPHARMA

SUNPHARMA's price has consistently hovered around the lower end of analysts' projections. This pattern may reflect concerns regarding the company's ability to achieve its anticipated growth.

Recommendation changes over time:

Recommendations trend for SUNPHARMA
Recommendations trend for SUNPHARMA


SUNPHARMA has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see SUNPHARMA as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.